Table 3:

Diagnostic Utility in Detecting Intermediate-High AD Neuropathological Changes or Intermediate-High AD Neuropathological Changes as Primary Pathology

	A. Intermediate-high ADNC n=101, 45 I/H ADNC			B. AD as Primary Pathology n=101, 34 I/H ADNC primary pathology
	PIB	FDG	P	PIB	FDG	P
Sensitivity (%)	96 [89–100]	80 [68–92]	.02	97 [91–100]	94 [86–100]	.31
Specificity (%)	86 [76–95]	84 [74–93]	.80	73 [62–84]	81 [71–90]	.30
Positive Likelihood Ratio	6.7 [3.5–12.7]	5 [2.7–9.2]	.52	3.6 [2.4–5.4]	4.8 [3–8]	.35
Negative Likelihood Ratio	0.05 [0.01–0.2]	0.24 [0.13–0.43]	.03	0.04 [.01–0.28]	0.07 [.02–.28]	.40
Positive Predictive Value (%)	84 [74–94]	80 [68–92]	.53	65 [52–78]	71 [58–84]	.34
Negative Predictive Value (%)	96 [91–100]	84 [74–93]	.01	98 [94–100]	96 [92–100]	.38
Accuracy (%)	90 [83–95]	82 [73–89]	.15	81 [72–88]	85 [77–91]	.54

Diagnostic utility of PIB and FDG in (A) detecting the presence of AD pathology (intermediate to high ADNC as the primary or secondary pathological diagnosis); and (B) detecting AD (intermediate to high ADNC) as the primary pathological diagnosis.

Diagnostic utility is presented as percentage [95% confidence interval]

Abbreviations: PIB – ¹¹C- Pittsburgh compound B; FDG – ¹⁸F fluorodeoxyglucose; ADNC – Alzheimer’s disease neuropathological changes; I/H – Intermediate/High